Allergy (and clinical immunology)
21.0K views | +5 today
Allergy (and clinical immunology)
Ressources et Actualités pour la spécialité Allergie
Your new post is loading...
Your new post is loading...
Scooped by Gilbert C FAURE
October 17, 12:46 PM
Scoop.it!

Allergy care has changed. And in many ways, that is a good thing. The old approach often looked like this: ↳ Avoid more and more things ↳ Blame every symptom on a positive test ↳ Wait until… |...

Allergy care has changed. And in many ways, that is a good thing. The old approach often looked like this: ↳ Avoid more and more things ↳ Blame every symptom on a positive test ↳ Wait until… |... | Allergy (and clinical immunology) | Scoop.it
Allergy care has changed.
And in many ways, that is a good thing.

The old approach often looked like this:
↳ Avoid more and more things
↳ Blame every symptom on a positive test
↳ Wait until symptoms get bad
↳ Treat everyone the same
↳ Reach for short-term relief again and again
↳ Make a plan only after a reaction happens

That is not the direction we want to keep going.

Better allergy care is more precise.

It starts with the right question:
What is actually going on here?

Because sneezing, wheezing, eczema, hives, and food reactions are not all the same problem.
And they should not all be treated the same way.

The newer approach is more thoughtful:

1️⃣ Targeted avoidance
Avoid only confirmed triggers, not everything “just in case.”

2️⃣ History plus testing
A test alone does not diagnose allergy. Test results need context.

3️⃣ Earlier control of inflammation
For asthma, rhinitis, and eczema, the goal is not just to chase flares. It is to control disease earlier.

4️⃣ Personalized care
Rhinitis, asthma, eczema, food allergy, and hives each need their own strategy.

5️⃣ Long-term tools when needed
Sprays, inhalers, skin care, allergy shots, biologics, and food allergy planning all have a role in the right patient.

6️⃣ Prevention and action plans
Education matters. Follow-up matters. Knowing what to do in a reaction matters.

7️⃣ Early food introduction for babies
One of the biggest shifts has been infant feeding.

The old idea was to delay common allergenic foods like peanut and egg.

Now we know that, when babies are developmentally ready, early introduction of common allergenic foods can help lower food allergy risk, especially in the right setting and with the right guidance.

So the “new way” is not doing more for the sake of doing more.

It is doing the right thing, for the right condition, at the right time.

That means less fear.
Less guesswork.
And better care.

What change in allergy care do you think patients or even clinicians still misunderstand the most?
No comment yet.
Scooped by Gilbert C FAURE
October 7, 4:51 AM
Scoop.it!

More peanuts in pregnancy ≠ less peanut allergy in babies. A major new NEJM trial just tested this. For years, families have asked whether eating more peanut during pregnancy could lower their… | ...

More peanuts in pregnancy ≠ less peanut allergy in babies. A major new NEJM trial just tested this. For years, families have asked whether eating more peanut during pregnancy could lower their… | ... | Allergy (and clinical immunology) | Scoop.it
More peanuts in pregnancy ≠ less peanut allergy in babies.
A major new NEJM trial just tested this.

For years, families have asked whether eating more peanut during pregnancy could lower their baby’s risk of developing peanut allergy.

Now we have much better data.

A new randomized trial included more than 2,100 pregnancies in families at higher risk for allergic disease.

One group was asked to eat at least:
🥜 60 peanuts per week
🥚 6 eggs per week

They continued this during pregnancy and through the first 4 months after delivery while breastfeeding.

The comparison group ate substantially less peanut and egg.

At 1 year of age, the babies were evaluated for IgE-mediated peanut or egg allergy.
The result?

7.8% of babies in the high peanut-and-egg group developed peanut or egg allergy.
8.4% in the comparison group did.

That difference was not statistically significant.

So eating substantially more peanut and egg during pregnancy and breastfeeding did not prevent food allergy in the baby.

But here is the important part:

This does not mean peanut exposure does not matter.

The stronger evidence for prevention comes after the baby is born.

Early introduction of peanut into an infant’s diet, followed by regular ingestion, can reduce the risk of developing peanut allergy.

So the practical message for parents is:

👉 You generally do not need to avoid peanut or egg during pregnancy just to prevent allergy.

👉 Eating extra peanut during pregnancy has not been shown to prevent peanut allergy.

👉 Introducing allergenic foods at the right time during infancy still matters.

Food allergy prevention may be less about what mom eats during pregnancy and more about when the baby starts eating the food.

Were you ever told to eat more, or avoid, certain foods during pregnancy because of allergy risk?

No comment yet.
Scooped by Gilbert C FAURE
July 29, 1:42 PM
Scoop.it!

🧬 Molecular Allergology: A New Way of Understanding Allergic Diseases For many years, we simply referred to allergies as being caused by peanuts, peaches, house dust mites, shrimp, or latex. Toda...

🧬 Molecular Allergology: A New Way of Understanding Allergic Diseases For many years, we simply referred to allergies as being caused by peanuts, peaches, house dust mites, shrimp, or latex. Toda... | Allergy (and clinical immunology) | Scoop.it
🧬 Molecular Allergology: A New Way of Understanding Allergic Diseases

For many years, we simply referred to allergies as being caused by peanuts, peaches, house dust mites, shrimp, or latex. Today, thanks to molecular allergology, we know that it is not only the allergen source that matters, but, more importantly, the individual allergenic proteins it contains.

These proteins, known as molecular allergens, and particularly pan-allergens, explain why the same patient may react to several seemingly unrelated allergen sources. For example, allergy to house dust mites may be associated with reactions to crustaceans, latex allergy may be linked to reactions to certain fruits, and peanut allergy may share homologous proteins with other legumes or tree nuts.

The identification of these molecular allergens has profoundly transformed our understanding of allergic diseases. It now enables far more accurate diagnosis, improved assessment of the risk of severe allergic reactions, better interpretation of sensitization profiles, and truly personalized patient management.

This illustration, entitled “The Allergome Metropolis”, offers an original way of visualizing this complex network of cross-reactivity. Inspired by a metropolitan transit map, each line represents a family of pan-allergens, while each station represents a major molecular allergen, allowing clinicians, researchers, and students to instantly appreciate the molecular relationships between different allergen sources.

🔬 The future of allergology is molecular. Understanding allergenic proteins means understanding allergic diseases with a level of precision that was unimaginable just a few years ago.
No comment yet.
Scooped by Gilbert C FAURE
March 9, 2025 5:34 AM
Scoop.it!

Robert Lufkin MD on LinkedIn: How Pediatricians Created the US Peanut Allergy…

Robert Lufkin MD on LinkedIn: How Pediatricians Created the US Peanut Allergy… | Allergy (and clinical immunology) | Scoop.it
How Pediatricians Created the US Peanut Allergy Epidemic

https://lnkd.in/gKGQyhnS
No comment yet.
Scooped by Gilbert C FAURE
February 10, 2025 6:32 AM
Scoop.it!

Clinical utility analysis of the Hoxb8 mast cell activation test for the diagnosis of peanut allergy

No comment yet.
Scooped by Gilbert C FAURE
April 23, 2022 11:06 AM
Scoop.it!

How one study changed what we know about peanut allergy

How one study changed what we know about peanut allergy | Allergy (and clinical immunology) | Scoop.it
Research from King’s, led by Professor Gideon Lack and Dr Alexandra Santos, has made ground-breaking in-roads to our understanding of food allergy. Their work has changed the global understanding of peanut allergy and informed work on other food allergies, such as eggs, milk, shellfish and tree...
No comment yet.
Scooped by Gilbert C FAURE
January 26, 2022 8:18 AM
Scoop.it!

Peanut allergy: one in five children achieved lasting remission after oral immunotherapy, study reports | The BMJ

Peanut allergies affect 2% of children in western countries and are one of the most common causes of food related deaths in the UK.Standard care is dietary avoidance and access to self-injectable adrenaline (epinephrine), although a new treatment called Palforzia, containing peanut protein powder,...
No comment yet.
Scooped by Gilbert C FAURE
December 23, 2020 6:19 AM
Scoop.it!

Aimmune's peanut allergy treatment Palforzia approved in EU - FirstWord Pharma

Aimmune's peanut allergy treatment Palforzia approved in EU - FirstWord Pharma | Allergy (and clinical immunology) | Scoop.it
FirstWord Pharma - Gain Access to the Information You Need Track the Companies,
Products, and Regulatory Areas of Most Interest to You
No comment yet.
Scooped by Gilbert C FAURE
May 9, 2020 4:43 AM
Scoop.it!

Divergent T follicular helper cell requirement for IgA and IgE production to peanut during allergic sensitization | Science Immunology

Divergent T follicular helper cell requirement for IgA and IgE production to peanut during allergic sensitization | Science Immunology | Allergy (and clinical immunology) | Scoop.it
No comment yet.
Scooped by Gilbert C FAURE
March 5, 2020 2:12 PM
Scoop.it!

Origins of peanut allergy-causing antibodies | Science

Origins of peanut allergy-causing antibodies | Science | Allergy (and clinical immunology) | Scoop.it
Some people produce immunoglobulin E (IgE) antibodies to proteins in common foods. As a result, these foods can trigger severe allergic inflammation (anaphylaxis). There are several structurally and functionally distinct antibody isotypes (IgM, IgD, IgG, IgA, and IgE), and which isotype binds to a target molecule (antigen) influences what happens next. For example, IgG that binds peanut proteins is harmless, but IgE bound to the same proteins can induce anaphylaxis and death. Therefore, how, where, and why allergen-reactive IgE is made are decades-old questions. Hoh et al. (1) found that gut tissue is a likely place for IgE development in peanut-allergic individuals. In addition, despite vast sequence possibilities, they found that many individuals share similar peanut-reactive IgE DNA sequences. This suggests that IgE antibodies in different individuals recognize peanut proteins in a similar manner, which could inform strategies for pharmacological interventions. Antibodies are produced by cells of the B lymphocyte lineage and consist of four Ig polypeptide chains—two identical heavy (H) chains and two identical light (L) chains—and each chain has a variable (V) region and a constant (C) region. The V region forms the surface that physically binds to antigens such as peanut proteins. The C region of IgH (CH) dictates antibody function largely by triggering processes that lead to neutralization, elimination, or induction of inflammation. Assembly of multiple IGH gene segments through the process of V(D)J recombination results in enormous sequence diversity, particularly in the exon encoding the V region, which comprises much of the antigen binding surface. Next to the V exon are a variety of C-region exons arranged in tandem (e.g., Cµ, Cγ, Cε, and Cα), which define the different antibody isotypes (2). Newly assembled Ig is produced as IgM. However, during an immune response, the same V region of IgH (VH) can be expressed in the context of another C-region isotype through a process called class switch recombination (CSR). This positions an alternative CH region next to the VH exon by permanent excision of the intervening DNA and associated CH-encoding exons. The position of CH exons relative to each other thus determines which IgH isotypes are available for secondary switch events. For example, an IgM-expressing B cell can switch to IgG1, and then that same IgG1+ B cell can switch to IgE because Cε is 3′ (downstream) to Cγ1 in the IGH locus. However, IgE-expressing B cells cannot switch to IgG1 (or any other isotype whose CH is positioned 5′ to Cε). Somatic hypermutation (SHM) further diversifies V regions by introducing mutations that can enhance affinity to antigen (3). The V(D)J recombination–, CSR-, and SHM-mediated processing of IGH enable phylogenetic mapping of how B-lineage cells and the antibodies they produce are related to one another. To gain insights into the origins of IgE production and the relationships between antibody-producing cells, Hoh et al. sequenced the IGH genes from B-lineage plasma cells in upper digestive tract tissues of 19 peanut-allergic individuals and compared them with those of nonallergic controls. They found more IgE-expressing cells in gut tissue in food-allergic individuals, confirming previous findings (4). Multiple clonally related VH-encoding sequences in IgE antibodies were also shared with other IgH isotypes. These findings suggest that B cells undergo CSR to IgE in the gut tissue as opposed to undergoing CSR to IgE elsewhere before migrating to the gut. This is different to the case of bone marrow, which is a major destination for antibody-producing cells after CSR elsewhere. This raises an important question: What features of the gut environment favor CSR to IgE? Moreover, because the bone marrow is a major location of antibody production, including IgE in allergic disease (5), the degree to which gut-derived versus bone marrow–derived IgE affects clinical disease, prognosis, and treatment approaches remains to be determined (see the figure). Hoh et al. identified antibody sequences that are reactive to the peanut protein Ara h 2 (Arachis hypogaea allergen 2) and found groups of similar sequences among multiple individuals. Similar sequences were also found in analyses of IgE+ B cells from peripheral blood in individuals with peanut allergy (6), further validating the concept of convergent IgE development to peanut proteins. Nonallergic individuals also had Ara h 2–reactive sequences, but only in non-IgE isotypes such as IgM, IgG, and IgA. These findings highlight how antibodies that induce a food-allergic response are generated. The production of antibodies that bind peanut proteins does not seem to be the problem per se; instead, the switching of that antibody to the IgE isotype appears to be key. This is consistent with observations that humans make IgG to a variety of dietary proteins without correlation to food allergy (7). In addition, it is possible that IgG to food antigens may be protective from food allergy by either blocking IgE binding or otherwise interfering with IgE function (8, 9). Perhaps an intervention that discourages gut IgE CSR could prevent food allergy. The convergence of IgE sequences in multiple peanut-allergic individuals suggests that immune recognition may occur through antibody binding to a few finite regions on key proteins. In this regard, drugs that block IgE binding to these regions holds promise as a therapy in allergic disease. There is proof of principle: Two therapeutic monoclonal IgG antibodies against a cat allergen inhibited IgE binding, and treatment with the combination of these two antibodies alone was sufficient to reduce allergic symptoms in 34 cat-allergic individuals in a clinical trial (10). Blocking IgE to peanut antigens may be similarly efficacious. Although seemingly innocuous, food allergens may influence the gut environment to generate conditions that induce CSR to IgE. In this regard, allergenic foods may have properties that induce allergic inflammation, as has been proposed (11, 12). Understanding the influences of the gut microbiota, age of exposure, and environment on the regulation of allergic responses to food (13, 14) promises to provide clues to elucidating how IgE CSR is regulated. http://www.sciencemag.org/about/science-licenses-journal-article-reuse This is an article distributed under the terms of the Science Journals Default License. References and Notes ↵ R. A. Hoh et al., Sci. Immunol. 5, eaay4209 (2020). ↵ P. Tong, D. R. Wesemann, Curr. Top. Microbiol. Immunol. 388, 21 (2015).OpenUrl ↵ L. Mesin, J. Ersching, G. D. Victora, Immunity 45, 471 (2016).OpenUrlPubMed ↵ C. Caffarelli, E. Romanini, P. Caruana, M. E. Street, G. De' Angelis, Pediatr. Res. 44, 485 (1998).OpenUrlPubMed ↵ S. Asrat et al., Sci. Immunol. 5, eaav8402 (2020). ↵ D. Croote, S. Darmanis, K. C. Nadeau, S. R. Quake, Science 362, 1306 (2018). ↵ J. Gocki, Z. Bartuzi, Postepy Dermatol. Alergol. 33, 253 (2016).OpenUrl ↵ O. T. Burton et al., J. Allergy Clin. Immunol. 134, 1310 (2014).OpenUrlCrossRef ↵ O. T. Burton, J. M. Tamayo, A. J. Stranks, K. J. Koleoglou, H. C. Oettgen, J. Allergy Clin. Immunol. 141, 189 (2018).OpenUrl ↵ J. M. Orengo et al., Nat. Commun. 9, 1421 (2018).OpenUrlCrossRef ↵ M. Profet, Q. Rev. Biol. 66, 23 (1991). ↵ N. W. Palm, R. K. Rosenstein, R. Medzhitov, Nature 484, 465 (2012). ↵ O. I. Iweala, C. R. Nagler, Annu. Rev. Immunol. 37, 377 (2019).OpenUrl ↵ D. R. Wesemann, C. R. Nagler, Immunity 44, 728 (2016).OpenUrl Acknowledgments: D.R.W. is supported by the NIH (AI121394, AI139538, and AI137940), the Burroughs Wellcome Fund, and an anonymous donor. C.R.N. is supported by the NIH (AI106302, AI134923, and AI146099) and the Sunshine Charitable Foundation. C.R.N. is president and co-founder of ClostraBio, Inc.
No comment yet.
Rescooped by Gilbert C FAURE from Immunology and Biotherapies
January 14, 2020 4:37 AM
Scoop.it!

Intrommune: Cutting Edge Immunotherapy for Peanut Allergy Presented at Biotech Showcase 2020

Intrommune: Cutting Edge Immunotherapy for Peanut Allergy Presented at Biotech Showcase 2020 | Allergy (and clinical immunology) | Scoop.it
SAN FRANCISCO, CA / ACCESSWIRE / January 13, 2020 / Intrommune Therapeutics presented an update today on their oral mucosal immunotherapy (OMIT) technology at the Biotech Showcase™, which occurs during...

Via Krishan Maggon
No comment yet.
Scooped by Gilbert C FAURE
December 6, 2019 8:33 AM
Scoop.it!

Peanut Allergy Vaccine to Rewrite the Immune System

Peanut Allergy Vaccine to Rewrite the Immune System | Allergy (and clinical immunology) | Scoop.it
Peanut allergies could become a thing of the past as breakthrough research from the University of South Australia develops a radically novel vaccination that’s poised to cure the potentially life threatening condition.
No comment yet.
Scooped by Gilbert C FAURE
October 12, 4:07 AM
Scoop.it!

Not All Positive Food Allergy Tests Mean You're Allergic | Pragya Shrestha MD, FACAAI posted on the topic

Not All Positive Food Allergy Tests Mean You're Allergic | Pragya Shrestha MD, FACAAI posted on the topic | Allergy (and clinical immunology) | Scoop.it
Your child tested positive for a food allergy.
But does that mean they are actually allergic?

Not necessarily.

This is one of the most common misunderstandings I see in my allergy clinic.

A positive skin prick test or blood IgE test does not automatically mean someone has a food allergy.

It means their immune system has made IgE antibodies that recognize the food.

But whether eating that food will cause a reaction is a different question.

Here are 4 things a positive food allergy test can mean:

1️⃣ TRUE FOOD ALLERGY

The test is positive AND the clinical history supports an allergic reaction.

For example:
A child develops hives, vomiting, or wheezing shortly after eating peanuts, and peanut testing is positive.

The history and test results fit together.

2️⃣ SENSITIZATION WITHOUT ALLERGY

This is where confusion often begins.

A child may test positive to milk, egg, or peanut but eat that food regularly without any symptoms.

That is called sensitization.

And sensitization does not always mean allergy.

👉 If someone regularly eats a food without problems, a positive test alone is generally not a reason to remove it from their diet.

3️⃣ CROSS-REACTIVITY

Sometimes, the immune system recognizes proteins that look similar.

For example:

Someone with birch pollen allergy may test positive to apple or carrot because these foods contain proteins similar to birch pollen.

Some people develop itching in the mouth when eating these foods, called pollen-food allergy syndrome.

Others may have positive tests without symptoms.

A positive result does not always mean a dangerous food allergy.

4️⃣ AN ALLERGY THAT MAY HAVE BEEN OUTGROWN

This is particularly important in children.

Some children outgrow milk, egg, wheat, or other food allergies over time.

But their allergy tests may remain positive even after they develop tolerance.

That is why we look at:
↳ Previous reactions
↳ Changes in skin test or specific IgE results over time
↳ Whether a supervised oral food challenge is appropriate

An oral food challenge, performed under medical supervision, is the gold standard for confirming whether someone can tolerate a food when the diagnosis remains uncertain.

Here is what I wish more parents knew:

A positive test does not tell us the whole story.

And a larger skin test or higher IgE level does not reliably predict how severe a future reaction will be.

Testing should be guided by the clinical history, not used as a broad screening tool without a clear reason.

Unnecessary food avoidance can affect nutrition, quality of life, and create significant anxiety for families.

Before eliminating a food based only on a test result, discuss it with an allergist.

If there is a history of a possible allergic reaction, do not try reintroducing the food at home without appropriate guidance.

We treat patients, not just positive test results.

Have you or your child ever been told to avoid a food based only on a positive allergy test?
No comment yet.
Scooped by Gilbert C FAURE
August 6, 10:42 AM
Scoop.it!

Peanut allergy dropped 81%. Not from a new drug. From a baby snack. Here's how we found out. Jewish children living in the UK had about 10 times higher rates of peanut allergy than Jewish childre...

Peanut allergy dropped 81%. Not from a new drug. From a baby snack. Here's how we found out. Jewish children living in the UK had about 10 times higher rates of peanut allergy than Jewish childre... | Allergy (and clinical immunology) | Scoop.it
Peanut allergy dropped 81%.
Not from a new drug. From a baby snack.

Here's how we found out.

Jewish children living in the UK had about 10 times higher rates of peanut allergy than Jewish children living in Israel.

The genetics were nearly identical.

The environment was not.

Many Israeli infants regularly ate Bamba, a peanut puff snack, during infancy.

That observation led to one of the most important food allergy studies ever performed.

The LEAP trial enrolled 640 infants at high risk for peanut allergy (severe eczema, egg allergy, or both).

Half were introduced to peanut between 4 and 11 months of age and kept eating about 6 grams of peanut protein a week until age 5. The other half avoided peanut completely.

The numbers at age 5:

↳ 17.2% of the avoidance group developed peanut allergy

↳ 3.2% of the consumption group developed peanut allergy

↳ An 81% relative risk reduction

It held up. LEAP-On followed the same kids after 12 months off peanut:
18.6% allergic in the avoidance group vs. 4.8% in the consumption group.

LEAP-Trio followed them into adolescence: 15.4% vs. 4.4%.

Younger siblings introduced to peanut early had an 18.3% sensitization rate, vs. 44.4% in siblings who weren't (a different outcome measure than clinical allergy).

For context: peanut allergy prevalence in Western countries had roughly doubled over the decade before LEAP, reaching 1.4% to 3.0% of children, during the era when avoidance was standard advice.

But LEAP teaches us something beyond peanut.

Culture matters.

Families around the world introduce peanut, sesame, lentils, yogurt, fermented foods, and tree nuts at very different ages, and that may shape how the developing immune system learns what is safe.

Separately, some population-level observations (different literature than LEAP) suggest children raised on minimally processed, legume- and fish-rich diets have lower food allergy rates in parts of Asia compared with Western populations. Associative, not causal.

That does not mean one food, or one country's diet, is the answer.

Food allergy is influenced by many factors.

↳ Genetics

↳ Early food introduction

↳ Eczema and skin barrier health

↳ The microbiome

↳ Vitamin D and other environmental exposures

↳ Diet diversity and food processing

Most likely, it's the combination that determines risk.

One observation from Israeli children eating Bamba changed how we feed infants around the world.

Sometimes the biggest advances in medicine begin with someone noticing that one community does things differently.

The next breakthrough may already be happening in someone's kitchen.

Have you noticed cultural food practices that you think medicine should study more closely?
No comment yet.
Scooped by Gilbert C FAURE
May 15, 11:15 AM
Scoop.it!

Beyond Early Allergen Introduction: A New Paradigm for Pediatric Allergy Prevention 👶💡 ​As healthcare professionals, we’ve long focused on the timing of introducing peanuts and eggs to prevent… ...

Beyond Early Allergen Introduction: A New Paradigm for Pediatric Allergy Prevention 👶💡 ​As healthcare professionals, we’ve long focused on the timing of introducing peanuts and eggs to prevent… ... | Allergy (and clinical immunology) | Scoop.it
Beyond Early Allergen Introduction: A New Paradigm for Pediatric Allergy Prevention 👶💡

​As healthcare professionals, we’ve long focused on the timing of introducing peanuts and eggs to prevent food allergies. But a new EAACI interest group report (2025),co-authored by leading experts in the field such as Carina Venter , Emilia Vassilopoulou , Berber Vlieg-Boerstra RD PhD , and Alexandra Santos, MD PhD ,reminds us that the quality of the entire diet matters just as much.

​The latest guidance emphasizes a holistic "Healthy Complementary Feeding" approach to support immune maturation and a diverse gut microbiome.

​Key Clinical Takeaways:
⏱️ Timing is Key (4-6 Months): Start complementary feeding around this window to meet increasing needs for iron and zinc and to utilize the "window of opportunity" for immune tolerance.

​🥦 Prioritize Diversity: Encourage a high variety of whole, nutrient-dense, and home-cooked plant-based foods (vegetables, legumes, grains).

​🐟 Nutrient Focus: Aim for diets rich in fiber, iron, zinc, and omega-3 fatty acids, while including fermented foods like natural yogurt.

​🚫 The "Whole Food" Advantage: Discourage over-reliance on ultra-processed commercial baby foods and pouches, which are often low in nutrients and may delay the development of oral motor skills.

​🥜 Allergen Integration: Continue the early and regular introduction of regional allergens (especially egg and peanut), particularly for high-risk infants with eczema.

​By shifting our focus from "avoidance" to "diverse inclusion," we can better support the development of a healthy immune system in our youngest patients.

​Reference: Vlieg-Boerstra B, et al. Pediatr Allergy Immunol. 2025;36:e70150.
No comment yet.
Scooped by Gilbert C FAURE
January 14, 7:22 AM
Scoop.it!

#peanut #oral #immunotherapy | Juan Carlos Ivancevich

#peanut #oral #immunotherapy | Juan Carlos Ivancevich | Allergy (and clinical immunology) | Scoop.it
A very low maintenance dose of #peanut #oral #immunotherapy significantly increased tolerated peanut exposure and improved immunologic markers compared with strict avoidance, achieving desensitisation similar to a high dose. https://lnkd.in/dfAtjB2Y
No comment yet.
Scooped by Gilbert C FAURE
February 15, 2025 2:43 AM
Scoop.it!

National Institute of Allergy and Infectious Diseases (NIAID) on LinkedIn: #peanutallergy #niaid #nih #research #researchadvance #peanut #foodallergy…

National Institute of Allergy and Infectious Diseases (NIAID) on LinkedIn: #peanutallergy #niaid #nih #research #researchadvance #peanut #foodallergy… | Allergy (and clinical immunology) | Scoop.it
FOOD ALLERGY NEWS: Eating gradually increasing doses of store-bought, home-measured peanut butter for about 18 months in a clinical trial enabled 100% of…
No comment yet.
Scooped by Gilbert C FAURE
October 5, 2024 7:06 AM
Scoop.it!

Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy - PMC

Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy - PMC | Allergy (and clinical immunology) | Scoop.it
The prevalence of peanut allergy among children in Western countries has doubled in the past 10 years, and peanut allergy is becoming apparent in Africa and Asia. We evaluated strategies of peanut consumption and avoidance to determine which strategy ...
No comment yet.
Scooped by Gilbert C FAURE
February 16, 2022 9:25 AM
Scoop.it!

Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy | NEJM

Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy | NEJM | Allergy (and clinical immunology) | Scoop.it
Original Article from The New England Journal of Medicine — Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy...
No comment yet.
Scooped by Gilbert C FAURE
January 21, 2021 6:02 AM
Scoop.it!

First Real-World Effectiveness Analysis of Preschool Peanut Oral Immunotherapy

First Real-World Effectiveness Analysis of Preschool Peanut Oral Immunotherapy | Allergy (and clinical immunology) | Scoop.it
We previously described safety of preschool peanut oral immunotherapy (P-OIT) in a
real-world setting; 0.4% of patients experienced a severe reaction, and 4.1% received
epinephrine, during build-up.
No comment yet.
Scooped by Gilbert C FAURE
May 22, 2020 2:38 PM
Scoop.it!

Sialylation of immunoglobulin E is a determinant of allergic pathogenicity

Sialylation of immunoglobulin E is a determinant of allergic pathogenicity | Allergy (and clinical immunology) | Scoop.it
Approximately one-third of the world’s population suffers from allergies1. Exposure to allergens crosslinks immunoglobulin E (IgE) antibodies that are bound to mast cells and basophils, triggering the release of inflammatory mediators, including histamine2. Although IgE is absolutely required for allergies, it is not understood why total and allergen-specific IgE concentrations do not reproducibly correlate with allergic disease3–5. It is well-established that glycosylation of IgG dictates its effector function and has disease-specific patterns. However, whether IgE glycans differ in disease states or affect biological activity is completely unknown6. Here we perform an unbiased examination of glycosylation patterns of total IgE from individuals with a peanut allergy and from non-atopic individuals without allergies. Our analysis reveals an increase in sialic acid content on total IgE from individuals with a peanut allergy compared with non-atopic individuals. Removal of sialic acid from IgE attenuates effector-cell degranulation and anaphylaxis in several functional models of allergic disease. Therapeutic interventions—including removing sialic acid from cell-bound IgE with a neuraminidase enzyme targeted towards the IgE receptor FcεRI, and administering asialylated IgE—markedly reduce anaphylaxis. Together, these results establish IgE glycosylation, and specifically sialylation, as an important regulator of allergic disease. A specific type of glycosylation—sialylation—is more common on immunoglobulin E from individuals with a peanut allergys than from non-atopic people, suggesting that it has a role in regulating anaphylaxis.
No comment yet.
Scooped by Gilbert C FAURE
March 5, 2020 3:19 PM
Scoop.it!

Origins and clonal convergence of gastrointestinal IgE+ B cells in human peanut allergy | Science Immunology

Origins and clonal convergence of gastrointestinal IgE+ B cells in human peanut allergy | Science Immunology | Allergy (and clinical immunology) | Scoop.it
No comment yet.
Scooped by Gilbert C FAURE
February 5, 2020 4:31 AM
Scoop.it!

Palforzia becomes first peanut allergy drug to get US approval

Palforzia becomes first peanut allergy drug to get US approval | Allergy (and clinical immunology) | Scoop.it
The approval marks a “defining moment” for the peanut allergy community.- News - PharmaTimes...
No comment yet.
Rescooped by Gilbert C FAURE from Immunology and Biotherapies
December 8, 2019 10:29 AM
Scoop.it!

Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy

Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy | Allergy (and clinical immunology) | Scoop.it
Only some patients with peanut allergy undergoing oral immunotherapy (OIT) achieve
sustained clinical response. Basophil activation could provide a functional surrogate
of efficacy.

Via Krishan Maggon
No comment yet.